Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
NCT02693535Phase 2Recruiting
- Sponsor
- American Society of Clinical Oncology
- Start
- Mar 2016
- Primary completion
- Dec 2027
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of sunitinib, trastuzumab, pertuzumab, vemurafenib, cobimetinib in solid tumor (advanced stage), multiple myeloma (MM), non-Hodgkin lymphoma (NHL), sponsored by American Society of Clinical Oncology. Started Mar 2016; status: recruiting.
02
Drugs
03
Conditions
solid tumor (advanced stage)multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02693535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02693535.